Scrutinizer Report & Voting Results for 33 AGM
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Samrat Pharmachem Limited held its 33rd AGM on September 25, 2025 via video conferencing, with all 9 resolutions passed unanimously with 100% votes in favor. Key resolutions included adoption of audited financial statements for FY ended March 31, 2025, declaration of a dividend on equity shares for FY2024-25, and re-appointment of Mr. Lalit Mehta as Chairman & Managing Director, Mr. Rajesh Mehta as Executive Director, and Mr. Megh Mehta as Executive Director. A new Non-Executive Independent Director, Mr. Piyush Dharod, was also appointed, and the remuneration of Cost Auditors was ratified. The company had 6,864 shareholders on the record date (September 18, 2025), with 9 promoter group members and 29 public shareholders attending the meeting via VC.
Unanimous approval of all resolutions signals strong shareholder confidence and smooth governance with no dissent. The dividend declaration is a positive for shareholders, while continuity in key leadership roles (CMD and Executive Directors) provides stability. This is a routine but healthy AGM outcome with no governance red flags.